Welcome to the new scientist and researcher reference section. Your one-stop shop for the essential resources you need to advance your career.
January 17-19, 2019 | Palm Springs, CA
The 2019 SNMMI Mid-Winter and ACNM Annual Meeting is ready to get you to the heart of nuclear medicine and molecular imaging. Featuring tracks on general nuclear medicine and nuclear cardiology, as well as the full ACNM Annual Meeting program, the 2019 meeting offers you a small, focused meeting environment designed to maximize collaboration and discussion.
Don't miss the opportunity to learn from experts in the field in an intimate setting, increasing your level of expertise and providing information and techniques you can implement immediately when you return to work.
The most up-to-date and comprehensive source for nuclear medicine coding and reimbursement information on the web. Please note that ALL information and materials within the SNMMI Coding Corner are direct products of the SNMMI Coding and Reimbursement Working Group.
For Hospitals (APCs, IPPS) Find general coding and reimbursement information for hospitals.
For Private Practices (RBRVS) Find general coding and reimbursement information for professionals in private practices.
Coding and Reimbursement Q&A This easy to use feature contains over 100 questions and answers related to topics such as cardiac, endocrine, neurology, nuclear medicine-related drugs, oncology, PET, PET/CT, radiopharmaceuticals, and more!
In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.
SNMMI has a large body of knowledge in dose optimization that is continually growing and developing. The dose optimization website presents a wide variety of resources, including SNMMI journal articles, educational offerings, media-related information, links to useful websites and more.
The practice guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment. In the interest of creating strong, comprehensive documents, some guidelines were formally adopted by SNMMI in collaboration with other professional organizations.
SNMMI's Center for Molecular Imaging Innovation and Translation is an organizational component within the SNMMI that is dedicated to all aspects of molecular imaging in the detection and management of disease. The center is currently facilitating initiatives to bring molecular imaging discoveries from the lab to the patient and to advance "personalized" medicine.
The Clinical Trials Network’s mission is to advance the use of molecular imaging radiopharmaceuticals in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new agents to regulatory approval. Click here to learn more about the CTN’s Oncology and Neurology Scanner Validation programs, ongoing efforts to harmonize reconstruction parameters in oncology clinical trials, and other services that CTN offers to help scientists advance their research.
SNMMI educational programs are designed to meet the professional development needs of scientists involved in nuclear medicine and molecular imaging endeavors.
New research shows that molecular imaging—specifically, PSMA PET/MR—performs as well as currently used tools and provides additional information on tumor location that could help guide treatment for prostate cancer patients.
SNMMI submitted comments on USP General Chapter <825> on Friday, November 30th.
(Government Relations News)
Researchers have identified a promising second-generation positron emission tomography (PET) tracer for imaging and measuring tau pathology, contributing to understanding of Alzheimer’s and related dementias.
The December 2018 issue of The Journal of Nuclear Medicine is now available. Read about three novel tau radiopharmaceuticals for imaging patients with amyloid-positive Alzheimer disease, whole-body 68Ga-PSMA-11 PET/MR, immuno-PET after BACE-1 inhibition, and more. Also, check out the first in a new series of articles: "Discussions with Leaders."
Submit your abstract for the SNMMI 2019 Annual Meeting, June 22-25, in Anaheim, California, for the opportunity to present your research to a global audience of your peers, while increasing your professional recognition.
Original abstracts are being accepted on the following scientific tracks:
Abstract submission deadline:
Tuesday, January 8, 2019.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.
Learn more about books published by the Society of Nuclear Medicine and Molecular Imaging and the Technologist Section.